معرفی
C. Michael Gibson, MD is a leading interventional cardiologist, cardiovascular researcher, and educator at Harvard Medical School, where he serves as the Chief Executive Officer of the Baim Institute and PERFUSE Research Institute. These institutes have led over 1,000 studies and 5,500 peer-reviewed publications, including 144 in the New England Journal of Medicine.
- Key Roles: Director of Coronary Care Unit, Cardiac Catheterization Laboratory Director, Chief of Cardiology, Vice Chairman of Medicine
- Education: BS, MS, and MD from the University of Chicago (Phi Beta Kappa, AOA), followed by training at Brigham and Women’s Hospital and Beth Israel Deaconess Medical Center
Research Focus: Pioneered the open artery and microvasculature hypothesis in heart attacks, developed widely used coronary blood flow measures (TIMI frame count, TIMI myocardial perfusion grade), and leads virtual clinical trials like the HEARTLINE trial of the Apple Watch. Current work includes Factor XI inhibitors (milvexian) and apolipoprotein AI infusions for cardiovascular disease.
Scientific Contributions: Over 148,000 citations, 659 publications, and leadership in guidelines like the Bleeding Academic Research Consortium. Notable trials include ANDexanet Alfa for anticoagulant reversal and the PEERLESS study comparing mechanical thrombectomy to thrombolysis in pulmonary embolism.
- Leadership: FDA Cardiorenal Panel member (2017–2021), founder of WikiDoc.org and ClinicalTrialsResults.org
- Media Influence: Chief Medical Correspondent for the American College of Cardiology, 435K+ social media followers
Scientific Awards: Consistently ranked among the world’s most highly cited authors (Thomson Reuters, 2014–present), 50 Most Influential Voices in Healthcare (Medika Life, 2021), and Boston’s Top Doctors (multiple years).
